Ligand (LGND)-AvenCell Deal: Most of the Funding Is Tied to Milestones
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is building a business model that differs from that of many drug developers.
Ligand Pharmaceuticals Inc (LGND)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bailard Inc Thomas Bailard | 1,400 | $437,318 | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $105.67 | 5,523 | $583,629.22 | 161,234 | 2025-05-09 | Filing | |
| $104.53 | 2,307 | $241,149.56 | 155,711 | 2025-05-09 | Filing | |
| $104.57 | 1,680 | $175,677.60 | 153,404 | 2025-05-09 | Filing | |
| $104.40 | 500 | $52,200.00 | 27,932 | 2025-05-09 | Filing | |
| $103.89 | 1,000 | $103,890.00 | 27,432 | 2025-05-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $320.43 | 700 | $224,298.27 | 108,758 | 2026-11-02 | Filing | |
| $320.49 | 50 | $16,024.50 | 109,458 | 2026-10-30 | Filing | |
| $320.42 | 1,209 | $387,384.39 | 109,508 | 2026-10-30 | Filing | |
| $320.24 | 52 | $16,652.48 | 110,717 | 2026-10-30 | Filing | |
| $318.23 | 50 | $15,911.50 | 110,769 | 2026-10-30 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 658,556 | $205,713,138 | 1.33% | |
| 2. | 551,225 | $172,186,097 | 3.99% | |
| 3. | 50,367,000 | $84,804,647 | 0.57% | |
| 4. | 126,842 | $39,621,636 | 0.02% | |
| 5. | 69,350 | $21,662,860 | 2.68% |
News See All
Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book
On August 6, Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results showing royalty revenue up 32% year over year, just weeks after the company closed its acquisition of XOMA Royalty...
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2026 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2026 Earnings Call Transcript May 9, 2026 Operator: Hello, everyone.
What Makes Ligand Pharmaceuticals (LGND) an Investment Choice?
Summers Value Partners, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2025 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2025 Earnings Call Transcript November 8, 2025 Operator: Thank you for standing by. Welcome to Ligand Third Quarter 2025 Earnings Call.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2025 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2025 Earnings Call Transcript August 7, 2025Ligand Pharmaceuticals Incorporated beats earnings expectations.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2025 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2025 Earnings Call Transcript May 8, 2025Ligand Pharmaceuticals Incorporated beats earnings expectations.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Call Transcript February 27, 2025Ligand Pharmaceuticals Incorporated misses on earnings expectations.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2024 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2024 Earnings Call Transcript November 8, 2024 Operator: Good morning. My name is Aaron, and I will be your conference operator for today.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2024 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2024 Earnings Call Transcript August 6, 2024Ligand Pharmaceuticals Incorporated misses on earnings expectations.